ReviewInflammopharmacology2025
Naturally derived bioactive compounds as precision modulators of immune and inflammatory mechanisms in psoriatic conditions.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Large-scale comparative virtual screening identifies novel molecular targets underlying the multi-target activity of quercetin in psoriasis.Inflammopharmacology · 2026Article
- Lipid-based nanocarriers for antifungal drug delivery.Discover nano · 2026Review
- A Molecular-Dynamics-Guided Screening Pipeline Identifies Topical Glucocorticoid Receptor Modulators with Selective Epidermal Activation.Skin pharmacology and physiology · 2026Article
- Article
- Integrated Assessment of Inflammatory and Lipid-Metabolic Biomarkers in Psoriasis: Implications for Metabolic Syndrome.Life (Basel, Switzerland) · 2026Article
- Methotrexate Exposure and Inflammatory-Metabolic Biomarker Networks in Hospitalized Patients with Psoriasis: A Network Analysis Approach.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Interaction of Ferroptosis and Immune-Mediated Inflammation in Psoriasis.Antioxidants (Basel, Switzerland) · 2026Review
- Exploring the therapeutic potential of naturally occurring taxifolin, a dietary flavonoid: an updated comprehensive review.Frontiers in pharmacology · 2026Review
- Suppressive effect of topical moxifloxacin on imiquimod-induced model of psoriasis in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Tracing Five Decades of Psoriasis Pharmacotherapy: A Large-Scale Bibliometric Investigation with AI-Guided Terminology Normalization.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Mapping Emerging Scientific Trends in Chronic Skin Disorders Using Machine Learning-Based Bibliometrics.Bioengineering (Basel, Switzerland) · 2025Article
- New Perspectives on Nutraceutical Insulin Sensitizing Agents in the Treatment of Psoriasis and Other Dermatological Diseases.International journal of molecular sciences · 2025Review
- A Multimodal Approach to Managing Severe Psoriasis Vulgaris: A Case Report Leveraging Natural Therapies for Flare Control.Life (Basel, Switzerland) · 2025Article
- Targeting psoriatic inflammation with natural compounds: mechanistic insights and therapeutic promise.Inflammopharmacology · 2025Review
- Paris saponin VII attenuates psoriasiform inflammation by regulating STAT3/NFκB signaling pathway and Caspase-1-induced pyroptosis.Molecular medicine (Cambridge, Mass.) · 2025Article
- A Closer Look at the Dermatological Profile of GLP-1 Agonists.Diseases (Basel, Switzerland) · 2025Review
- Harnessing the Power ofMolecules (Basel, Switzerland) · 2025Review
- What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review.Journal of clinical medicine · 2025Review
- Anti-Inflammatory Effects of Curcumin-Based Nanoparticles Containing α-Linolenic Acid in a Model of Psoriasis In Vitro.Nutrients · 2025Article
- Understanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis represents a chronic autoimmune skin condition defined by various clinical forms, including inverse, erythrodermic, pustular, guttate, plaque types. While current therapies, including topical treatments but also systemic through conventional synthetic drugs and biologics, have improved symptom management, no treatment completely cures the disease, and numerous options are linked to considerable adverse effects, including immunosuppression and carcinogenic risks. Therefore, there is growing interest in bioactive compounds from natural sources due to their potential to reduce inflammation and oxidative stress in psoriasis with fewer adverse effects. The present narrative review aimed to address the limitations of current psoriasis therapies by exploring the therapeutic potential of bioactive compounds in the classes of flavonoids, terpenoids, omega-3 fatty acids, and alkaloids assessed through complex experimental models, focusing on their immunomodulatory and anti-inflammatory properties. Recent studies highlight the efficacy of natural bioactive compounds in reducing psoriasis symptoms, either as standalone treatments or in combination with conventional therapies. While these compounds show promise in alleviating psoriasis-related inflammation, further research is needed to optimize their therapeutic use, understand their mechanisms of action, and assess long-term safety. Future studies should focus on clinical trials to establish standardized protocols for incorporating bioactive compounds into psoriasis management and explore their potential role in personalized treatment strategies. Continued research is essential to develop more effective, safer, and affordable therapeutic options for psoriasis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.